The approval of a controversial new drug for Alzheimer’s disease, Aduhelm, is shining a spotlight on mild cognitive impairment (MCI) — problems with memory, attention, language or other cognitive tasks that exceed changes expected with normal aging.
Democracy Dies in Darkness
New Alzheimer’s drug is for those with mild cognitive impairment. But who has that disorder?
By Judith Graham
September 26, 2021 at 8:00 a.m. EDT